Paper Details

  1. Home
  2. Paper Details

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.

Author: BazhenovaLyudmila, CantariniMireille, ChangGee-Chen, ChuQuincy, CrinoLucio, DunphyFrank, GhiorghiuSerban, GossGlenwood, HanJi-Youn, HidaToyoaki, JuanOscar, KangJin-Hyoung, LeeJong Seok, MajemMargarita, MannHelen, MitsudomiTetsuya, NishioMakoto, SatouchiMiyako, ShepherdFrances A, TsaiChun-Ming

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

Osimertinib is an effective and safe treatment for non-small cell lung cancer patients with a specific EGFR mutation who have progressed after other EGFR inhibitors.
Paper Details　
Original Abstract of the Article :
Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR Thr790Met resistance mutation. We assessed the efficacy and safety of osimertinib in patients with EGFR Thr790Met-positive non-small-...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1470-2045(16)30508-3

データ提供：米国国立医学図書館（NLM）

Osimertinib for EGFR Thr790Met-Positive Advanced Non-Small-Cell Lung Cancer

The fight against [non-small-cell lung cancer (NSCLC)] is an ongoing battle, with researchers constantly seeking new and effective therapies. This research explores the potential of [osimertinib], an oral, potent, and irreversible [EGFR tyrosine-kinase inhibitor], for treating patients with [EGFR Thr790Met-positive advanced NSCLC] who have progressed after previous treatments. The authors conducted a [single-arm, phase 2 study] to evaluate the efficacy and safety of osimertinib in this specific patient population. Their findings demonstrate the promising potential of osimertinib in achieving [objective response] and [disease control], offering a beacon of hope for patients with this challenging disease. It's like discovering a new oasis in a harsh desert, providing a source of relief and a pathway towards better health.

Osimertinib: A Potential Oasis in the Desert of NSCLC

This study provides encouraging evidence for the efficacy and safety of osimertinib in treating EGFR Thr790Met-positive advanced NSCLC. The findings highlight the importance of personalized medicine, tailoring treatment strategies to the specific genetic characteristics of each patient. It's like understanding the unique challenges of navigating each part of the desert and choosing the right tools for each terrain.

Navigating the Desert of Lung Cancer

This research underscores the ongoing progress in the development of targeted therapies for NSCLC, offering new hope for patients. It encourages us to remain optimistic and to support further research to develop even more effective and personalized treatment approaches. It's like embarking on a journey through a vast and unforgiving desert; with each new discovery, we get closer to finding a cure and bringing solace to those affected by this disease.

Dr.Camel's Conclusion

This study presents a promising oasis in the desert of NSCLC treatment. By understanding the genetic landscape of this disease, we can develop more effective and personalized therapies, bringing hope to those battling this challenging illness.

Date :
  1. Date Completed 2017-05-29
  2. Date Revised 2022-06-03
Further Info :

Pubmed ID

27751847

DOI: Digital Object Identifier

10.1016/S1470-2045(16)30508-3

Related Literature

Article Analysis
・Side Effects of osimertinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.